Exploratory objectives
TG, hepatic lipase mass

To evaluate the effect of ARO-ANG3 on change from baseline in fasting LDL-C, total cholesterol, non-HDL-C, HDL-C, VLDL-C, TG, Lp(a), total ApoB, ApoB 48, ApoB 100, ApoC III, ApoC II, ApoA V, LPL mass (if feasible), hepatic lipase mass (if feasible), cholesteryl ester transfer protein (CETP) mass (if feasible) and ApoA I (all values drawn after at least 8-h fast)To evaluate the effect of doses of ARO-ANG3 on changes from baseline in BMITo evaluate the effect of ARO-ANG3 on changes from baseline in fasting serum blood glucose, hemoglobin A1c, C peptide, glucose tolerance test and fasting serum insulinTo evaluate the effect of ARO-ANG3 on change from baseline liver fat content using MRI-PDFF in cohort 5 onlyTo evaluate the effect of ARO-ANG3 on change from baseline in post-prandial (post-standardized high-fat/high-carbohydrate meal) serum TGs in specified cohortsTo evaluate excretion of ARO-ANG3 (full length and metabolites) and identify metabolites in plasma and urine in the multi-dose HP cohorts